Peptidomics Technologies and Applications in Drug Research

Proteomics in Drug Research

Volumn , Issue , 2006, Pages 113-135

  Schrader, Michael ^a   Budde, Petra ^b   Rose, Horst ^b   Lamping, Norbert ^b   Schulz Knappe, Peter ^b   Zucht, Hans Dieter ^b  

^a UNIVERSITY OF APPLIED SCIENCES WEIHENSTEPHAN TRIESDORF   (Germany)

^b BioVisioN AG   (Germany)

Author keywords

Applications of differential display peptidomics; Development of peptidomics technologies; Peptides in drug research; Peptidomics technologies and applications in drug research

Indexed keywords

BIOMARKERS; DRUG INTERACTIONS; ENZYME ACTIVITY; GENE EXPRESSION; MASS SPECTROMETRY; MOLECULAR BIOLOGY; PEPTIDES; PHYSIOLOGICAL MODELS; PHYSIOLOGY; TARGETED DRUG DELIVERY;

DIFFERENTIAL DISPLAY; DRUG RESEARCH; ENZYME LINKED IMMUNOSORBENT ASSAY; MASS SPECTROMETRY ANALYSIS; PEPTIDOMICS; PHYSIOLOGICAL FUNCTIONS; TECHNOLOGIES AND APPLICATIONS; THERAPEUTIC INTERVENTION;

CONTROLLED DRUG DELIVERY;

EID: 84945282969     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/3527608230.ch6     Document Type: Chapter

References (105)

1. Acher, R., Chauvet, J. (1953). The structure of bovine vasopressin. Biochim. Biophys. Acta 12, 487-488.
2. Acher, R., Light, A., Du Vigneaud, V. (1958). Purification of oxytocin and vasopressin by way of a protein complex. J. Biol. Chem. 233, 116-120.
3. Adams, S., Miller, G. T., Jesson, M. I., Watanabe, T., Jones, B., Wallner, B. P. (2004). PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent anti-tumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism. Cancer Res. 64, 5471-5480.
4. Aebersold, R., Mann, M. (2003). Mass spectrometry-based proteomics. Nature 422, 198-207.
5. Ahren, B., Landin-Olsson, M., Jansson, P. A., Svensson, M., Holmes, D., Schweizer, A. (2004). Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J. Clin. Endocrinol. Metab. 89, 2078-2084.
6. Anderson, L., Seilhamer, J. (1997). A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 18, 533-537.
7. Anderson, N. L., Anderson, N. G. (2002). The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell Proteomics 1, 845-867.
8. Andersson, L., Blomberg, L., Flegel, M., Lepsa, L., Nilsson, B., Verlander, M. (2000). Large-scale synthesis of peptides. Biopolymers 55, 227-250.
9. Antelmann, H., Tjalsma, H., Voigt, B., Ohlmeier, S., Bron, S., van Dijl, J. M., Hecker, M. (2001). A proteomic view on genome-based signal peptide predictions. Genome Res. 11, 1484-1502.
10. Baggerman, G., Verleyen, P., Clynen, E., Huybrechts, J., De Loof, A., Schoofs, L. (2004). Peptidomics. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 803, 3-16.
11. Banting, F. G., Best, C. H., Collip, J. B., Campbell, W. R., Fletcher, A. A. (1991). Pancreatic extracts in the treatment of diabetes mellitus: preliminary report 1922. CMAJ 145, 1281-1286.
12. Bergquist, J., Ekman, R. (2001). Future aspects of psychoneuroimmunology - lymphocyte peptides reflecting psychiatric disorders studied by mass spectrometry. Arch. Physiol. Biochem. 109, 369-371.
13. Blennow, K., Hampel, H. (2003). CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2, 605-613.
14. Bucknall, M., Fung, K. Y., Duncan, M. W. (2002). Practical quantitative biomedical applications of MALDI-TOF mass spectrometry. J. Am. Soc. Mass Spectrom. 13, 1015-1027.
15. Bures, E. J., Courchesne, P. L., Douglass, J., Chen, K., Davis, M. T., Jones, M. D., McGinley, M. D., Robinson, J. H., Spahr, C. S., Sun, J., Wahl, R. C., Patterson, S. D. (2001). Identification of incompletely processed potential carboxypeptidase E substrates from CpEfat/CpEfat mice. Proteomics 1, 79-92.
16. Burgus, R., Dunn, T. F., Desiderio, D., Ward, D. N., Vale, W., Guillemin, R. (1970). Characterization of ovine hypothalamic hypophysiotropic TSH-releasing factor. Nature 226, 321-325.
17. Carrette, O., Demalte, I., Scherl, A., Yalkinoglu, O., Corthals, G., Burkhard, P., Hochstrasser, D. F., Sanchez, J. C. (2003). A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 3, 1486-1494.
18. Chen, Y., Yu, P., Luo, J., Jiang, Y. (2003). Secreted protein prediction system combining CJ-SPHMM, TMHMM, PSORT. Mamm. Genome 14, 859-865.
19. Chen, Y. D., Zheng, S., Yu, J. K., Hu, X. (2004). Application of serum protein pattern model in diagnosis of colorectal cancer. Zhonghua Zhong Liu Za Zhi 26, 417-420.
20. Clynen, E., Baggerman, G., Veelaert, D., Cerstiaens, A., Van der Horst, D., Harthoorn, L., Derua, R., Waelkens, E., De Loof, A., Schoofs, L. (2001). Peptidomics of the pars inter-cerebralis-corpus cardiacum complex of the migratory locust, Locusta migratoria. Eur. J. Biochem. 268, 1929-1939.
21. Conarello, S. L., Li, Z., Ronan, J., Roy, R. S., Zhu, L., Jiang, G., Liu, F., Woods, J., Zycband, E., Moller, D. E., Thornberry, N. A., Zhang, B. B. (2003). Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc. Natl. Acad. Sci. USA 100, 6825-6830.
22. Davidsson, P., Brinkmalm, A., Karlsson, G., Persson, R., Lindbjer, M., Puchades, M., Folkesson, S., Paulson, L., Dahl, A., Rymo, L., Silberring, J., Ekman, R., Blennow, K. (2003). Clinical mass spectrometry in neuroscience Proteomics and peptidomics. Cell Mol. Biol. (Noisy-le-grand) 49, 681-688.
23. de Meester, I., Lambeir, A. M., Proost, P., Scharpe, S. (2003). Dipeptidyl peptidase IV substrates An update on in vitro peptide hydrolysis by human DPPIV. Adv. Exp. Med. Biol. 524, 3-17.
24. DiMasi, J. A. (2002). The value of improving the productivity of the drug development process: faster times and better decisions. Pharmacoeconomics 20 (Suppl. 3), 1-10.
25. DiMasi, J. A., Hansen, R. W., Grabowski, H. G. (2003). The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151-185.
26. Drucker, D. J. (2003). Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 26, 2929-2940.
27. Fenn, J. B., Mann, M., Meng, C. K., Wong, S. F., Whitehouse, C. M. (1989). Electrospray ionization for mass spectrometry of large biomolecules. Science 246, 64-71.
28. Forssmann, W. G., Schulz-Knappe, P., Schrader, M., Opitz, H. G. (1996). Process for determining the status of an organism by peptide measurement [WO 98/07036] 13-8-1996. Published 19-2-1998.
29. Frank, R., Hargreaves, R. (2003). Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discov. 2, 566-580.
30. Fricker, L. D., Berman, Y. L., Leiter, E. H., Devi, L. A. (1996). Carboxypeptidase E activity is deficient in mice with the fat mutation Effect on peptide processing. J. Biol. Chem. 271, 30619-30624.
31. Gänshirt, D., Harms, F., Schulz-Knappe, P. (2005). Peptidomics in Drug Development. Editio Cantor Verlag, Aulendorf.
32. Galas, D. J. (2001). Sequence interpretation. Making sense of the sequence. Science 291, 1257-1260.
33. Ganz, T. (2004). Defensins: antimicrobial peptides of vertebrates. C. R. Biol. 327, 539-549.
34. Gygi, S. P., Rochon, Y., Franza, B. R., Aebersold, R. (1999). Correlation between protein and mRNA abundance in yeast. Mol. Cell Biol. 19, 1720-1730.
35. Hancock, R. E., Lehrer, R. (1998). Cationic peptides: a new source of antibiotics. Trends Biotechnol. 16, 82-88.
36. Harris, R. B. (1989). Processing of pro-hormone precursor proteins. Arch. Biochem. Biophys. 275, 315-333.
37. Hobbs, R. E. (2003). Using BNP to diagnose, manage, treat heart failure. Cleve Clin. J. Med. 70, 333-336.
38. Holst, J. J., Deacon, C. F. (2004). Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. Curr. Opin. Pharmacol. 4, 589-596.
39. Ilyin, S. E., Belkowski, S. M., Plata-Salaman, C. R. (2004). Biomarker discovery and validation: technologies and integrative approaches. Trends Biotechnol. 22, 411-416.
40. Jackson, R. S., Creemers, J. W., Ohagi, S., Raffin-Sanson, M. L., Sanders, L., Montague, C. T., Hutton, J. C., O'Rahilly, S. (1997). Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nat. Genet. 16, 303-306.
41. Jimenez, C. R., Li, K. W., Dreisewerd, K., Mansvelder, H. D., Brussaard, A. B., Reinhold, B. B., Van der Schors, R. C., Karas, M., Hillenkamp, F., Burbach, J. P., Costello, C. E., Geraerts, W. P. (1997). Pattern changes of pituitary peptides in rat after salt-loading as detected by means of direct, semiquantitative mass spectrometric profiling. Proc. Natl. Acad. Sci. USA 94, 9481-9486.
42. John, H., Standker, L. (2004). Peptide separation and analysis. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 803, 1-2.
43. Karas, M., Bachmann, D., Bahr, U., Hillenkamp, F. (1987). Matrix-assisted ultraviolet laser desorption of non-volatile compounds. Int. J. Mass Spectrom. Ion Processes 78, 53-68.
44. Karas, M. (1996). Matrix-assisted laser desorption ionization MS: a progress report. Biochem. Soc. Trans. 24, 897-900.
45. Karl, J., Borgya, A., Gallusser, A., Huber, E., Krueger, K., Rollinger, W., Schenk, J. (1999). Development of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit. Scand. J. Clin. Lab. Invest. Suppl. 230, 177-181.
46. Kelleher, N. L. (2004). Top-down proteomics. Anal. Chem. 76, 197A-203A.
47. Kettman, J. R., Coleclough, C., Frey, J. R., Lefkovits, I. (2002). Clonal proteomics: one gene - family of proteins. Proteomics 2, 624-631.
48. Kochendoerfer, G. (2003). Protein & Peptide Drug Delivery - Third International Conference. Minimally invasive delivery methods 22-23 September 2003, Philadelphia, PA, USA. IDrugs 6, 1043-1045.
49. Lamers, J., Selle, H., Scapozza, L., Crameri, R., Schulz-Knappe, P., Mohring, T., Kellmann, M., Khamenia, V., Zucht, H.-D. (2005). Correlation-associated peptide networks of human cerebrospinal fluid. Proteomics 5, 2789-2798.
50. Leiter, E. H. (1997). Carboxypeptidase E and obesity in the mouse. J. Endocrinol. 155, 211-214.
51. Lesko, L. J., Atkinson, A. J. (2001). Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu. Rev. Pharmacol. Toxicol. 41, 347-366.
52. Li, L., Garden, R. W., Sweedler, J. V. (2000). Single-cell MALDI: a new tool for direct peptide profiling. Trends Biotechnol. 18, 151-160.
53. Marguet, D., Baggio, L., Kobayashi, T., Bernard, A. M., Pierres, M., Nielsen, P. F., Ribel, U., Watanabe, T., Drucker, D. J., Wagtmann, N. (2000). Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc. Natl. Acad. Sci. USA 97, 6874-6879.
54. Mentlein, R., Gallwitz, B., Schmidt, W. E. (1993). Dipeptidyl-peptidase IV hydrolyzes gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 214, 829-835.
55. Miklos, G. L., Maleszka, R. (2001). Protein functions and biological contexts. Proteomics 1, 169-178.
56. Möhring, T., Kellmann, M., Jürgens, M., Schrader, M. (2005). Top-down identification of endogenous peptides up to 9 kDa in cerebrospinal fluid and brain tissue by nanoelectrospray quadrupole time-of-flight tandem mass spectrometry. J. Mass Spectrom. 40, 214-226.
57. Mutt, V. (1992). On the necessity of isolating peptides. In Schneider, C. H., Eberle, A. N. (Eds.), Peptides. ESCOM, Leiden, pp. 3-20.
58. Naggert, J. K., Fricker, L. D., Varlamov, O., Nishina, P. M., Rouille, Y., Steiner, D. F., Carroll, R. J., Paigen, B. J., Leiter, E. H. (1995). Hyperproinsulinaemia in obese fat/fat mice associated with a carboxypeptidase E mutation which reduces enzyme activity. Nat. Genet. 10, 135-142.
59. Niwa, T., Takeuchi, H., Hino, T., Kawashima, Y. (1995). Aerosolization of lactide/glycolide copolymer (PLGA) nanospheres for pulmonary delivery of peptide-drugs. Yakugaku Zasshi 115, 732-741.
60. Overall, C. M., Tam, E. M., Kappelhoff, R., Connor, A., Ewart, T., Morrison, C. J., Puente, X., Lopez-Otin, C., Seth, A. (2004). Protease degradomics: mass spectrometry discovery of protease substrates and the CLIP-CHIP, a dedicated DNA microarray of all human proteases and inhibitors. Biol. Chem. 385, 493-504.
61. Owens, D. R. (2002). New horizons - alternative routes for insulin therapy. Nat. Rev. Drug Discov. 1, 529-540.
62. Pandey, A., Mann, M. (2000). Proteomics to study genes and genomes. Nature 405, 837-846.
63. Pearson, J. D., Lin, N. T., Regnier, F. E. (1982). The importance of silica type for reverse-phase protein separations. Anal. Biochem. 124, 217-230.
64. Petricoin, E. F., Liotta, L. A. (2004). SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr. Opin. Biotechnol. 15, 24-30.
65. Pfützner, A., Kunt, T., Hohberg, C., Mondok, A., Pahler, S., Konrad, T., Lubben, G., Forst, T. (2004). Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes. Diabetes Care 27, 682-687.
66. Puente, X. S., Sanchez, L. M., Overall, C. M., Lopez-Otin, C. (2003). Human and mouse proteases: a comparative genomic approach. Nat. Rev. Genet. 4, 544-558.
67. Pusch, W., Flocco. M. T., Leung, S. M., Thiele, H., Kostrzewa, M. (2003). Mass spectrometry-based clinical proteomics. Pharmacogenomics 4, 463-476.
68. Raida, M., Schulz-Knappe, P., Heine, G., Forssmann, W. G. (1999). Liquid chromatography and electrospray mass spectrometric mapping of peptides from human plasma filtrate. J. Am. Soc. Mass Spectrom. 10, 45-54.
69. Ramstrom, M., Bergquist, J. (2004). Miniaturized proteomics and peptidomics using capillary liquid separation and high resolution mass spectrometry, FEBS Lett. 567, 92-95.
70. Rawlings, N. D., Tolle, D. P., Barrett, A. J. (2004). MEROPS: the peptidase database. Nucleic Acids Res. 32, Database issue, D160-D164.
71. Rehfeld, J. F. (1998). The new biology of gastrointestinal hormones. Physiol. Rev. 78, 1087-1108.
72. Rehfeld, J. F., Goetze, J. P. (2003). The post-translational phase of gene expression: new possibilities in molecular diagnosis. Curr. Mol. Med. 3, 25-38.
73. Reimer, M. K., Holst, J. J., Ahren, B. (2002). Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur J. Endocrinol. 146, 717-727.
74. Richardson, P. L. (2002). The determination and use of optimized protease substrates in drug discovery and development. Curr. Pharm. Des. 8, 2559-2581.
75. Richter, R., Schulz-Knappe, P., Schrader, M., Standker, L., Jürgens, M., Tammen, H., Forssmann, W. G. (1999). Composition of the peptide fraction in human blood plasma: database of circulating human peptides. J. Chromatogr. B Biomed. Sci. Appl. 726, 25-35.
76. Roepstorff, P. (1997). Mass spectrometry in protein studies from genome to function. Curr. Opin. Biotechnol. 8, 6-13.
77. Rose, K., Bougueleret, L., Baussant, T., Bohm, G., Botti, P., Colinge, J., Cusin, I., Gaertner, H., Gleizes, A., Heller, M., Jimenez, S., Johnson, A., Kussmann, M., Menin, L., Menzel, C., Ranno, F., Rodriguez-Tome, P., Rogers, J., Saudrais, C., Villain, M., Wetmore, D., Bairoch, A., Hochstrasser, D. (2004). Industrial-scale proteomics: from liters of plasma to chemically synthesized proteins. Proteomics 4, 2125-2150.
78. Rosenfeld, L. (2002). Insulin: discovery and controversy. Clin. Chem. 48, 2270-2288.
79. Sanger, F. (1959). Chemistry of insulin; determination of the structure of insulin opens the way to greater understanding of life processes. Science 129, 1340-1344.
80. Sasaki, K., Sato, K., Akiyama, Y., Yanagihara, K., Oka, M., Yamaguchi, K. (2002). Peptidomics-based approach reveals the secretion of the 29-residue COOH-terminal fragment of the putative tumor suppressor protein DMBT1 from pancreatic adenocarcinoma cell lines. Cancer Res. 62, 4894-4898.
81. Sato, K., Sasaki, K., Tsao, M. S., Yamaguchi, K. (2002). Peptide differential display of serum-free conditioned medium from cancer cell lines. Cancer Lett. 176, 199-203.
82. Schrader, M., Jürgens, M., Hess, R., Schulz-Knappe, P., Raida, M., Forssmann, W. G. (1997). Matrix-assisted laser desorption/ionisation mass spectrometry guided purification of human guanylin from blood ultra-filtrate. J. Chromatogr. A 776, 139-145.
83. Schrader, M., Schulz-Knappe, P. (2001). Peptidomics technologies for human body fluids. Trends Biotechnol. 19, S55-S60.
84. Schulz-Knappe, P., Schrader, M., Standker, L., Richter, R., Hess, R., Jürgens, M., Forssmann, W. G. (1997). Peptide bank generated by large-scale preparation of circulating human peptides. J. Chromatogr. A 776, 125-132.
85. Schulz-Knappe, P., Zucht, H. D., Heine, G., Jürgens, M., Hess, R., Schrader, M. (2001). Peptidomics: the comprehensive analysis of peptides in complex biological mixtures. Comb. Chem. High Throughput Screen 4, 207-217.
86. Scrivener, E., Barry, R., Platt, A., Calvert, R., Masih, G., Hextall, P., Soloviev, M., Terrett, J. (2003). Peptidomics: A new approach to affinity protein microarrays. Proteomics 3, 122-128.
87. Sechi, S., Oda, Y. (2003). Quantitative proteomics using mass spectrometry. Curr. Opin. Chem. Biol. 7, 70-77.
88. Seidah, N. G., Chretien, M. (1999). Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides. Brain Res. 848, 45-62.
89. Sewald, N., Jakubke H-D (2002). Peptides: Chemistry and Biology. Wiley-VCH, Weinheim.
90. Sillard, R., Jornvall, H., Carlquist, M., Mutt, V. (1993). Chemical assay for cyst(e)ine-rich peptides detects a novel intestinal peptide ZF-1, homologous to a single zinc-finger motif. Eur. J. Biochem. 211, 377-380.
91. Southan, C. (2004). Has the yo-yo stopped? An assessment of human protein-coding gene number. Proteomics 4, 1712-1726.
92. Steiner, D. F. (2002). The prohormone convertases and precursor processing in protein biosynthesis. In Dalbey, R. E., Sigman, D. S. (Eds.), The enzymes: coand post-translational proteolysis of proteins, Vol. XXII. Academic, San Diego.
93. Stoeckli, M., Chaurand, P., Hallahan, D. E., Caprioli, R. M. (2001). Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat. Med. 7, 493-496.
94. Tammen, H., Kreipe, H., Hess, R., Kellmann, M., Lehmann, U., Pich, A., Lamping, N., Schulz-Knappe, P., Zucht, H. D., Lilischkis, R. (2003). Expression profiling of breast cancer cells by differential peptide display. Breast Cancer Res. Treat 79, 83-93.
95. Tammen, H., Schulte, I., Hess, R., Mencel, C., Kellmann, M., Mohring, T., Schulz-Knappe, P. (2005). Peptidomic analysis of human blood specimens: comparison between plasma specimens and serum by differential peptide display. Proteomics 5, 414-422.
96. Uttenweiler-Joseph, S., Moniatte, M., Lagueux, M., Van Dorsselaer, A., Hoffmann, J. A., Bulet, P. (1998). Differential display of peptides induced during the immune response of Drosophila: A matrix-assisted laser desorption ionization time-of-flight mass spectrometry study. Proc. Natl. Acad. Sci. USA 95, 11342-11347.
97. Verhaert, P., Uttenweiler-Joseph, S., de Vries, M., Loboda, A., Ens, W., Standing, K. G. (2001). Matrix-assisted laser desorption/ionization quadrupole time-of-flight mass spectrometry: an elegant tool for peptidomics. Proteomics 1, 118-131.
98. Villanueva, J., Philip, J., Entenberg, D., Chaparro, C. A., Tanwar, M. K., Holland, E. C., Tempst, P. (2004). Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal. Chem. 76, 1560-1570.
99. Walgren, J. L., Thompson, D. C. (2004). Application of proteomic technologies in the drug development process. Toxicol. Lett. 149, 377-385.
100. Wang, W., Zhou, H., Lin, H., Roy, S., Shaler, T. A., Hill, L. R., Norton, S., Kumar, P., Anderle, M., Becker, C. H. (2003). Quantification of proteins and metabolites by mass spectrometry without isotopic labeling or spiked standards. Anal. Chem. 75, 4818-4826.
101. Wei, C. M., Heublein, D. M., Perrella, M. A., Lerman, A., Rodeheffer, R. J., McGregor, C. G., Edwards, W. D., Schaff, H. V., Burnett, J. C. Jr. (1993). Natriuretic peptide system in human heart failure. Circulation 88, 1004-1009.
102. Wieland, T., Bodanszky, M. (1991). The World of Peptides. A Brief History of Peptide Chemistry. Springer-Verlag, Berlin.
103. Yamamoto, K., Burnett, J. C. Jr., Jougasaki, M., Nishimura, R. A., Bailey, K. R., Saito, Y., Nakao, K., Redfield, M. M. (1996). Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 28, 988-994.
104. Zasloff, M. (1987). Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc. Natl. Acad. Sci. USA 84, 5449-5453.
105. Zolg, J. W., Langen, H. (2004). How industry is approaching the search for new diagnostic markers and biomarkers. Mol. Cell Proteomics 3, 345-354.